Brief: Windtree Presents Data From Positive Seismic Phase 2 Study Of Istaroxime
23/05/2022 20:07
May 23 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE PRESENTS DATA FROM ITS POSITIVE SEISMIC PHASE 2
STUDY OF ISTAROXIME IN EARLY CARDIOGENIC SHOCK IN A LATE-BREAKER
PRESENTATION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE
MEETING IN MADRID
Source text for Eikon: urn:newsml:reuters.com:*:nGNX2FNMq1
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study